LTRNLantern Pharma Inc.

Nasdaq lanternpharma.com


$ 5.42 $ -0.43 (-7.45 %)    

Friday, 19-Apr-2024 15:58:08 EDT
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 5.34
$ 5.58
$ 0.00 x 0
$ 0.00 x 0
$ 5.34 - $ 5.58
$ 2.38 - $ 11.99
235,218
na
57.9M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-20-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-01-2021 09-30-2021 10-Q
11 07-29-2021 06-30-2021 10-Q
12 05-03-2021 03-31-2021 10-Q
13 03-10-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 07-30-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 recap-lantern-pharma-q4-earnings
Recap: Lantern Pharma Q4 Earnings
03/18/2024 20:30:21

 lantern-pharma-q4-2023-gaap-eps-039-beats-048-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.48...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

 lantern-pharma-earnings-preview
Lantern Pharma Earnings Preview
03/15/2024 15:00:52

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 box-reports-upbeat-earnings-joins-american-public-education-wave-life-sciences-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

 lantern-pharmas-ai-platform-radr-surpasses-60b-data-points-anticipates-reaching-100b-data-points-in-2024-paving-the-way-for-enhanced-cancer-therapy-innovations-and-expedited-development-timelines

The rapid growth of Lantern Pharma's AI platform could lead to accelerated development of better treatments, greater precis...

 lantern-pharma-advances-adc-program-across-multiple-solid-tumor-cancers

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-co...

 fda-grants-lantern-pharma-orphan-drug-designation-for-drug-candidate-lp-284-in-high-grade-b-cell-lymphomas

The Orphan Drug Designation strengthens LP-284's clinical development path and can provide for additional market exclusivit...

 lantern-pharma-awarded-orphan-designation-status-for-n-hydroxy-n-methylacylfulveneurea-for-the-treatment-of-diffuse-large-b-cell-lymphomahigh-grade-b-cell-lymphoma-with-myc-and-bcl2-rearrangements

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=971823

 lantern-pharma-q3-2023-gaap-eps-029-beats-045-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.45...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION